EClinicalMedicine (Jul 2024)
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyResearch in context
- Alizée Bozonnat,
- Marie Beylot-Barry,
- Olivier Dereure,
- Michel D’Incan,
- Gaëlle Quereux,
- Emmanuella Guenova,
- Marie Perier-Muzet,
- Stephane Dalle,
- Florent Grange,
- Manuelle-Anne Viguier,
- Caroline Ram-Wolff,
- Laurence Feldmeyer,
- Helmut Beltraminelli,
- Nathalie Bonnet,
- Florent Amatore,
- Eve Maubec,
- Nathalie Franck,
- Laurent Machet,
- François Chasset,
- Florence Brunet-Possenti,
- Jean-David Bouaziz,
- Maxime Battistella,
- Marie Donzel,
- Anne Pham-Ledard,
- Claudia Bejar,
- Hélène Moins-Teisserenc,
- Samia Mourah,
- Philippe Saiag,
- Ewa Hainaut,
- Catherine Michel,
- Guido Bens,
- Henri Adamski,
- François Aubin,
- Serge Boulinguez,
- Pascal Joly,
- Billal Tedbirt,
- Isabelle Templier,
- Laura Troin,
- Henri Montaudié,
- Saskia Ingen-Housz-Oro,
- Sarah Faiz,
- Laurent Mortier,
- Gabor Dobos,
- Martine Bagot,
- Matthieu Resche-Rigon,
- Claire Montlahuc,
- Arnaud Serret-Larmande,
- Adèle de Masson
Affiliations
- Alizée Bozonnat
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
- Marie Beylot-Barry
- Department of Dermatology, CHU de Bordeaux, BoRdeaux Institute of Oncology, BRIC INSERM U1312, INSERM BoRdeaux Institute of Oncology, Team 5, Université de Bordeaux, Bordeaux, France
- Olivier Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
- Michel D’Incan
- Department of Dermatology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
- Gaëlle Quereux
- Department of Dermatology, Nantes University Hospital, CIC 1413, Inserm UMR 1302/EMR6001 INCIT, F-44000 Nantes, France
- Emmanuella Guenova
- Department of Dermatology, University Hospital Lausanne, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
- Marie Perier-Muzet
- Department of Dermatology, Hospices Civils de Lyon, Lyon, France
- Stephane Dalle
- Department of Dermatology, Hospices Civils de Lyon, Lyon, France
- Florent Grange
- Department of Dermatology, CH de Valence, France
- Manuelle-Anne Viguier
- Department of Dermatology, Université Reims-Champagne Ardenne, EA7509-IRMAIC, Reims, France
- Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France
- Laurence Feldmeyer
- Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- Helmut Beltraminelli
- Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- Nathalie Bonnet
- Department of Dermatology, CHU de Marseille, Marseille, France
- Florent Amatore
- Department of Dermatology, CHU de Marseille, Marseille, France
- Eve Maubec
- Department of Dermatology, Avicenne Hospital, AP-HP, Bobigny, France
- Nathalie Franck
- Department of Dermatology, CHU Cochin, Paris, France
- Laurent Machet
- Department of Dermatology, CHU de Tours, Tours, France
- François Chasset
- Department of Dermatology, CHU Tenon, Faculty of Medicine, Sorbonne University, Paris, France
- Florence Brunet-Possenti
- Department of Dermatology, CHU Bichat, Paris, France
- Jean-David Bouaziz
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
- Maxime Battistella
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France; Pathology Laboratory, Saint-Louis Hospital, AP-HP, Paris, France
- Marie Donzel
- Pathology Laboratory, Hospices Civils de Lyon, Lyon, France
- Anne Pham-Ledard
- Department of Dermatology, CHU de Bordeaux, BoRdeaux Institute of Oncology, BRIC INSERM U1312, INSERM BoRdeaux Institute of Oncology, Team 5, Université de Bordeaux, Bordeaux, France
- Claudia Bejar
- Department of Dermatology, Avicenne Hospital, AP-HP, Bobigny, France
- Hélène Moins-Teisserenc
- Université Paris Cité, Paris, France; Hematology Laboratory, Saint-Louis Hospital, AP-HP, Paris, France
- Samia Mourah
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France; Department of Pharmacogenomics and Oncogenetics, Saint-Louis Hospital, AP-HP, Paris, France
- Philippe Saiag
- Department of Dermatology, Ambroise-Paré Hospital, AP-HP, & EA 4340 “Biomarkers in Cancerology and Hemato-Oncology”, UVSQ, Université Paris-Saclay, 92104, Boulogne-Billancourt, France
- Ewa Hainaut
- Department of Dermatology, CHU de Poitiers, Poitiers, France
- Catherine Michel
- Department of Dermatology, CH Mulhouse, Groupe Hospitalier Mulhouse Sud Alsace, Mulhouse, France
- Guido Bens
- Department of Dermatology, CHU Orléans, Orléans, France
- Henri Adamski
- Department of Dermatology, CHU Pontchaillou, Rennes, France
- François Aubin
- Department of Dermatology, CHU de Besançon, Besançon, France
- Serge Boulinguez
- Department of Dermatology, CHU de Toulouse, Toulouse, France
- Pascal Joly
- Department of Dermatology, CHU de Rouen, Rouen, France
- Billal Tedbirt
- Department of Dermatology, CHU de Rouen, Rouen, France
- Isabelle Templier
- Department of Dermatology, CHU de Grenoble, Grenoble, France
- Laura Troin
- Department of Dermatology, CHU de Nice, Nice, France
- Henri Montaudié
- Department of Dermatology, CHU de Nice, Nice, France
- Saskia Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor Hospital, APHP, Créteil, France
- Sarah Faiz
- Department of Dermatology, CHU Lille, Lille, France
- Laurent Mortier
- Department of Dermatology, CHU Lille, Lille, France
- Gabor Dobos
- Department of Dermatology, Charité Hospital, Berlin, Germany
- Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
- Matthieu Resche-Rigon
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France; Department of Biostatistics, Saint-Louis Hospital, AP-HP, Paris, France
- Claire Montlahuc
- Department of Biostatistics, Saint-Louis Hospital, AP-HP, Paris, France
- Arnaud Serret-Larmande
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France; Department of Biostatistics, Saint-Louis Hospital, AP-HP, Paris, France
- Adèle de Masson
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France; Corresponding author. Department of Dermatology, National Reference Center for Cutaneous Lymphomas, Saint-Louis Hospital, 1 avenue Claude Vellefaux, F-75010, Paris, France.
- Journal volume & issue
-
Vol. 73
p. 102679
Abstract
Summary: Background: Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors in Sézary syndrome, including treatment with mogamulizumab, in a real-life setting. Methods: Data from patients with Sézary (ISCL/EORTC stage IV) and pre-Sézary (stage IIIB) syndrome diagnosed from 2000 to 2020 were obtained from 24 centers in Europe. Age, disease stage, plasma lactate dehydrogenases levels, blood eosinophilia at diagnosis, large-cell transformation and treatment received were analyzed in a multivariable Cox proportional hazard ratio model. This study has been registered in ClinicalTrials (SURPASSe01 study: NCT05206045). Findings: Three hundred and thirty-nine patients were included (58% men, median age at diagnosis of 70 years, Q1-Q3, 61–79): 33 pre-Sézary (9.7% of 339), 296 Sézary syndrome (87.3%), of whom 10 (2.9%) had large-cell transformation. One hundred and ten patients received mogamulizumab. Median follow-up was 58 months (95% confidence interval [CI], 53–68). OS was 46.5% (95% CI, 40.6%–53.3%) at 5 years. Multivariable analysis showed that age ≥ 80 versus <50 (HR: 4.9, 95% CI, 2.1–11.2, p = 0.001), and large-cell transformation (HR: 2.8, 95% CI, 1.6–5.1, p = 0.001) were independent and significant factors associated with reduced OS. Mogamulizumab treatment was significantly associated with decreased mortality (HR: 0.34, 95% CI, 0.15–0.80, p = 0.013). Interpretation: Treatment with mogamulizumab was significantly and independently associated with decreased mortality in Sézary syndrome. Funding: French Society of Dermatology, Swiss National Science Foundation (IZLIZ3_200253/1) and SKINTEGRITY.CH collaborative research program.
